Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Bastiano Sanna Sells 422 Shares of Stock

Posted by on May 10th, 2023

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) EVP Bastiano Sanna sold 422 shares of the company’s stock in a transaction that occurred on Friday, May 5th. The shares were sold at an average price of $350.03, for a total value of $147,712.66. Following the transaction, the executive vice president now directly owns 34,888 shares of the company’s stock, valued at approximately $12,211,846.64. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Bastiano Sanna also recently made the following trade(s):

  • On Monday, May 8th, Bastiano Sanna sold 2,850 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $350.00, for a total value of $997,500.00.
  • On Tuesday, May 2nd, Bastiano Sanna sold 1,622 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $350.66, for a total value of $568,770.52.
  • On Wednesday, April 12th, Bastiano Sanna sold 7,567 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $326.70, for a total value of $2,472,138.90.
  • On Tuesday, April 4th, Bastiano Sanna sold 522 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $315.81, for a total value of $164,852.82.
  • On Thursday, March 16th, Bastiano Sanna sold 2,746 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $300.59, for a total value of $825,420.14.

Vertex Pharmaceuticals Trading Up 0.2 %

VRTX stock opened at $344.83 on Wednesday. The company’s 50-day simple moving average is $316.79 and its 200-day simple moving average is $308.52. The company has a quick ratio of 4.11, a current ratio of 4.28 and a debt-to-equity ratio of 0.03. Vertex Pharmaceuticals Incorporated has a 52-week low of $233.01 and a 52-week high of $354.46. The firm has a market cap of $88.81 billion, a P/E ratio of 27.45, a PEG ratio of 3.23 and a beta of 0.49.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last posted its earnings results on Monday, May 1st. The pharmaceutical company reported $3.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.51 by $0.54. Vertex Pharmaceuticals had a net margin of 35.40% and a return on equity of 25.06%. The business had revenue of $2.37 billion for the quarter, compared to analyst estimates of $2.34 billion. During the same period in the prior year, the company posted $3.16 EPS. The company’s revenue for the quarter was up 13.2% on a year-over-year basis. As a group, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 12.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. StockNews.com assumed coverage on Vertex Pharmaceuticals in a report on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Barclays lifted their target price on Vertex Pharmaceuticals from $342.00 to $384.00 in a report on Tuesday, May 2nd. Piper Sandler reiterated a “neutral” rating and issued a $296.00 price target on shares of Vertex Pharmaceuticals in a research report on Wednesday, February 8th. Sanford C. Bernstein boosted their target price on Vertex Pharmaceuticals from $344.00 to $363.00 in a research report on Wednesday, May 3rd. Finally, Stifel Nicolaus boosted their target price on Vertex Pharmaceuticals from $300.00 to $340.00 in a research report on Tuesday, May 2nd. Five analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $352.59.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. BerganKDV Wealth Management LLC raised its holdings in Vertex Pharmaceuticals by 0.5% in the 1st quarter. BerganKDV Wealth Management LLC now owns 6,421 shares of the pharmaceutical company’s stock valued at $2,023,000 after acquiring an additional 31 shares during the last quarter. Farmers & Merchants Investments Inc. grew its stake in shares of Vertex Pharmaceuticals by 25.0% in the 3rd quarter. Farmers & Merchants Investments Inc. now owns 165 shares of the pharmaceutical company’s stock valued at $48,000 after buying an additional 33 shares during the period. TCI Wealth Advisors Inc. grew its stake in shares of Vertex Pharmaceuticals by 22.6% in the 4th quarter. TCI Wealth Advisors Inc. now owns 179 shares of the pharmaceutical company’s stock valued at $52,000 after buying an additional 33 shares during the period. Parkside Financial Bank & Trust grew its stake in shares of Vertex Pharmaceuticals by 7.7% in the 1st quarter. Parkside Financial Bank & Trust now owns 461 shares of the pharmaceutical company’s stock valued at $145,000 after buying an additional 33 shares during the period. Finally, Emfo LLC boosted its position in shares of Vertex Pharmaceuticals by 15.5% during the 3rd quarter. Emfo LLC now owns 254 shares of the pharmaceutical company’s stock worth $74,000 after purchasing an additional 34 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

(Get Rating)

Vertex Pharmaceuticals, Inc is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.

See Also

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.